



BOSE McKINNEY & EVANS LLP

CUSTOMER NUMBER 25267

2700 First Indiana Plaza
135 North Pennsylvania Street
Indianapolis, Indiana 46204
(317) 684-5000

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>Agent's File</i>	}	
<i>Reference:</i> 17695-0002	}	<i>U.S. Application No.: 10/554,068</i>
	}	
<i>Applicant:</i> Karl Kadler et al.	}	<i>International Application No.: PCT/GB04/01719</i>
	}	
<i>Invention:</i> Modified Peptides And Their Uses	}	<i>International Filing Date: 21 April 2004</i>
	}	
	}	<i>Priority Date: 22 April 2003</i>

CERTIFICATE OF MAILING TO COMMISSION OF PATENTS AND TRADEMARKS

Date of Mailing: September 26, 2006

Express Mail No. EV 654403066

I certify that documents listed below

- Submission of Sequence Listing (1 page) (in duplicate)
- Preliminary Amendment (3 pages)
- Sequence Listing (39 pages)
- Copy of the Notification to Comply With Requirements For Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures (2 pages)
- One (1) Computer Disk containing sequence listing
- Certificate of Mailing
- Return Receipt postcard (1 page)

are being deposited with the United States Postal Service "Express Mail" service under 37 CFR §1.10 on the date indicated above in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Respectfully submitted,

BOSE McKINNEY & EVANS LLP

Christine E.M. Orich – Registration No. 44,987

Indianapolis, Indiana
(317) 684-5000



UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/554,068	Karl Kadler	17695-0002

 25267
 BOSE MCKINNEY & EVANS LLP
 135 N PENNSYLVANIA ST
 SUITE 2700
 INDIANAPOLIS, IN 46204

RECEIVED

AUG 04 2006

BOSE MCKINNEY & EVANS

INTERNATIONAL APPLICATION NO.	
PCT/GB04/01719	
I.A. FILING DATE	PRIORITY DATE
04/21/2004	04/22/2003

CONFIRMATION NO. 2838

371 FORMALITIES LETTER



OC000000019819966

Date Mailed: 07/31/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.** Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

 1 Br
 8/7/06

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN R MCLEAN

Telephone: (703) 308-9140 EXT 214

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/554,068	PCT/GB04/01719	17695-0002

FORM PCT/DO/EO/922 (371 Formalities Notice)